

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Three Months Ended March 31,	
	2024	2023
Grant revenue	\$ -	\$ -
Operating expenses:		
Research and development	4,426	2,819
General and administrative	1,457	1,451
	5,883	4,270
Loss from operations	(5,883)	(4,270)
Other income (expense), net	33	233
Net loss	\$ (5,850)	\$ (4,037)
Net loss per common share	\$ 2.47	\$ 2.30
Weighted averages shares outstanding	2,367,050	1,755,905

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	March 31, 2024	December 31, 2023
	Assets	
Cash and cash equivalents	\$ 769	\$ 6,453
Other current assets	2,093	1,433
Total current assets	2,862	7,886
Property and other assets	496	1,397
Total assets	\$ 3,358	\$ 9,283
Liabilities and stockholders' equity		
Total liabilities	\$ 3,304	\$ 3,520
Stockholders' equity	54	5,763
Total liabilities and stockholders' equity	\$ 3,358	\$ 9,283
Common shares outstanding	2,308,309	1,977,152